Microdosing Retatrutide: What the Triple-Agonist Data Actually Show

Retatrutide is the most-hyped molecule in the GLP-1 conversation right now, and the microdosing crowd has noticed. The pitch writes itself: if a "triple agonist" produces eye-watering weight loss at full doses, surely a tiny fraction delivers plenty. There are two problems with that pitch, and both are serious. First, retatrutide is investigational — it is not FDA-approved for anything, so every gram of it sold for human use right now is gray-market, compounded, or research-grade product of uncertain provenance. Second, the trial data don't actually describe a "microdose": even retatrutide's lowest studied dose, 1 mg, is a real therapeutic dose that produced meaningful weight and liver-fat changes. "Microdosing retatrutide" means going below a dose floor that was itself the bottom of a clinical trial — into territory no one has studied at all.

This page lays out exactly what the retatrutide trials showed, at which doses, and why the microdosing framing falls apart on contact with the evidence.

What retatrutide is — and isn't

Retatrutide (development code LY3437943) is a single molecule that activates three receptors at once: the GIP receptor, the GLP-1 receptor, and — uniquely — the glucagon receptor ¹. That third arm is what separates it from tirzepatide (a dual GIP/GLP-1 agonist) and semaglutide (GLP-1 only). The glucagon component is thought to raise energy expenditure and drive liver-fat reduction, which is why retatrutide's liver results stand out.

But the single most important fact about retatrutide is regulatory: it is not approved by the FDA. As of October 2026 it remains investigational: Eli Lilly reported its first phase 3 results in May 2026, and in the same announcement said retatrutide is legally available only to participants in its clinical trials ¹⁰. There is no approved label, no approved dose, no pharmacy-dispensed finished drug. Anyone "microdosing retatrutide" is using a compounded or research-sourced version of an experimental drug — a categorically different risk picture from off-label use of an approved medicine.

The phase 2 obesity trial: even 1 mg did a lot

The anchor dataset is retatrutide's phase 2 obesity trial — a 48-week, double-blind, randomized, placebo-controlled study in 338 adults with obesity (or overweight plus a weight-related condition) ². The headline numbers at the higher doses are striking: at 48 weeks, mean weight loss reached about 22.8% at 8 mg and 24.2% at 12 mg, versus about 2.1% on placebo ².

Here's the part that matters for microdosing. The trial's lowest dose was 1 mg, and it was not a microdose — it produced a mean weight loss of about 7.2% at 24 weeks and 8.7% at 48 weeks, compared with roughly 1.6% and 2.1% on placebo ². So 1 mg is already a clinically meaningful, real dose. A "microdose" of retatrutide would, by definition, sit below that — below the lowest dose any trial has tested. That is unstudied territory: no efficacy data, no safety data, nothing but extrapolation.

And the trial shows a clean dose-response: 1 mg < 4 mg < 8 mg < 12 mg, with weight loss climbing at every step ². That gradient is the opposite of the microdosing thesis. It says more drug does more — so going below 1 mg should be expected to do less than the already-modest 1-mg result, not to magically preserve the benefit.

The liver-fat result — real, but at studied doses

The figure the microdosing pitch most loves to borrow is retatrutide's liver-fat reduction. In a substudy of participants with metabolic-dysfunction-associated steatotic liver disease (MASLD) and at least 10% liver fat, retatrutide cut liver fat dramatically: a mean relative reduction at 24 weeks of about 42.9% at 1 mg, 57.0% at 4 mg, 81.4% at 8 mg, and 82.4% at 12 mg, versus a 0.3% rise on placebo ³. Normal liver fat (under 5%) was reached by 27% of the 1-mg group and the large majority of higher-dose groups ³.

That ~43% liver-fat drop at 1 mg is real and impressive. But notice, again, the dose: it is the 1-mg arm — the trial's floor, not a microdose — and it follows the same climbing gradient as weight loss. There is no data point below 1 mg. Anyone citing "retatrutide drops liver fat 43%" to justify a sub-1-mg microdose is borrowing a studied-dose result for an unstudied dose. The honest read is that the liver benefit, like the weight benefit, was earned at real therapeutic doses and scales with the dose.

Diabetes and the broader evidence base

Retatrutide also has a phase 2 trial in type 2 diabetes, where it improved glycemic control and produced substantial weight loss across its dose range versus placebo and an active comparator ⁴. A 2025 systematic review and meta-analysis of retatrutide for obesity pooled the available phase 2 evidence and confirmed dose-dependent weight loss alongside the expected gastrointestinal side-effect profile ⁵. All of that is phase 2.

The first phase 3 results

On May 21, 2026, Lilly announced topline results from TRIUMPH-1, an 80-week, randomized, double-blind, placebo-controlled phase 3 trial in 2,339 adults with obesity, or overweight plus a weight-related condition, without diabetes ¹⁰. Average weight loss at 80 weeks was 19.0% at 4 mg, 25.9% at 9 mg and 28.3% at 12 mg ¹⁰. The same dose ladder shows up in the side effects: nausea was reported by 28.6%, 38.4% and 42.4% of people on 4, 9 and 12 mg, against 14.8% on placebo, and discontinuation for adverse events rose from 4.1% at 4 mg to 11.3% at 12 mg ¹⁰.

Two things in that release matter for microdosing. The lowest phase 3 dose is 4 mg, reached after a single step at 2 mg, so the phase 3 doses sit even further above a "microdose" than the phase 2 trial did. And these are company-reported topline figures for a drug that still has no FDA approval. The evidence has moved from "early" to "one large positive trial at full doses." It says nothing about a dose below 1 mg.

Why microdosing retatrutide is a gray-market bet

Stack the facts and the microdosing case collapses:

• •There is no approved retatrutide. Unlike semaglutide or tirzepatide — which at least have FDA-approved reference products behind their compounded copies — retatrutide has no approved version at all. Every dose is investigational. Compounding or sourcing an unapproved experimental drug carries documented risks: a pharmacovigilance analysis of compounded GLP-1 receptor agonists found sharply elevated reporting of preparation errors, contamination, and dosing mistakes ⁶. With an unapproved molecule, and the same goes for cagrilintide sold as a research peptide, there's no approved-product benchmark to even check purity against.
• •No microdose has been studied. The lowest trial dose, 1 mg, already produced ~7% weight loss and ~43% liver-fat reduction. Below that is a data vacuum.
• •The dose-response runs against you. Every retatrutide endpoint climbed with dose. The pattern predicts that going sub-therapeutic yields less, mirroring what dose-ranging data show for semaglutide ⁷ — not a shortcut to full benefit.
• •The class risks don't vanish at low doses. GLP-1-class drugs carry real gastrointestinal and other risks ⁸, and the broader microdosing literature is explicitly cautionary about DIY dosing and unregulated sourcing ⁹.

The honest bottom line: retatrutide's data are exciting, but they describe an investigational drug at real therapeutic doses — the lowest of which, 1 mg, is already meaningful. "Microdosing" it means using an unapproved experimental compound at a dose no study has ever examined, sourced through gray-market channels. That is not a measured, evidence-based choice; it is a guess layered on top of a gamble.

If what draws you to an investigational compound is the idea of a lower dose with a published curve behind it, there is now an approved drug that offers exactly that: the daily oral GLP-1 pill and its dose-response data covers the strongest evidence-based low-dose argument in the class, along with the two marketed strengths that have no efficacy data at all. For how this compares to the more-studied dual agonist, see microdosing tirzepatide: what the evidence actually says. For the dose-response logic in depth, read GLP-1 dose-response: why lower doses do less. For the sourcing and compounding risks that apply with extra force to an unapproved molecule, see is compounded / microdosed GLP-1 safe. And for the full evidence picture on the trend, start with our pillar, microdosing GLP-1: what the evidence actually shows, or compare options on our GLP-1 microdose rankings hub.